TrialSignal
Clinical trial intelligence report
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00087724-Jul 28, 2026
NCT ID
NCT00087724
Status
TERMINATED
Phase
Phase 2
Sponsor
Astellas Pharma Inc
Executive brief
Investment-Ready Snapshot
The clinical trial for FK962, sponsored by Astellas Pharma Inc, was designed to evaluate its safety and efficacy in patients with mild to moderate Alzheimer's disease. The trial was terminated, which raises concerns regarding the drug's viability in a competitive market characterized by a high demand for effective Alzheimer's treatments. Given the increasing prevalence of Alzheimer's disease, any potential therapeutic that demonstrates efficacy could capture significant market share. However, the termination of this trial suggests potential challenges in achieving desired clinical outcomes or safety profiles, necessitating further diligence on Astellas' pipeline and strategic direction in the Alzheimer's space.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00087724
Indication
Alzheimer's Disease
Modality
small molecule
Target
FK962 is a small molecule that is believed to modulate the activity of the immune system and may have neuroprotective effects, although the precise molecular target remains unspecified in the provided data.
Intervention
FK962
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.